BARSHAY STANLEY F

SEC source: 0001012975-18-000885 · edgar.xml · nonDerivative · entry 1

BARSHAY STANLEY F · CIK 0001266737 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,744

F1 · price: Represents an automatic grant of restricted stock under the Company's 2012 Incentive Compensation Plan valued at $81,000, issued as part of annual director compensation and approved by the Board of Directors of the Company on June 29, 2018. The number of shares was determined based on a stock price of $19.825, the average of the high and low trading prices of the Company's common stock on June 29, 2018, the date of the Company's Annual Meeting of Shareholders. The restricted stock will vest on March 2, 2019, the last day of the fiscal year of grant, provided that the director remains in office until the last day of the fiscal year.

SEC source: 0001012975-17-000510 · edgar.xml · nonDerivative · entry 1

BARSHAY STANLEY F · CIK 0001266737 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,658

F1 · price: Represents an automatic grant of restricted stock under the Company's 2012 Incentive Compensation Plan valued at $81,000, issued as part of annual director compensation and approved by the Board of Directors of the Company on June 29, 2017. The number of shares was determined based on a stock price of $30.3025, the average of the high and low trading prices of the Company's common stock on June 29, 2017, the date of the Company's Annual Meeting of Shareholders. The restricted stock will vest on March 3, 2018, the last day of the fiscal year of grant, provided that the director remains in office until the last day of the fiscal year.

SEC source: 0001209191-10-015042 · doc4.xml · derivative · entry 4

BARSHAY STANLEY F · CIK 0001266737 · ExVP&PresConsHlthCare

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,199

Underlying: Common Stock · 10,000 shares

Expires 2013-07-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-10-015042 · doc4.xml · nonDerivative · entry 2

BARSHAY STANLEY F · CIK 0001266737 · ExVP&PresConsHlthCare

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,589

SEC source: 0001209191-10-015042 · doc4.xml · nonDerivative · entry 1

BARSHAY STANLEY F · CIK 0001266737 · ExVP&PresConsHlthCare

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,589

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-10-014856 · doc4.xml · derivative · entry 11

BARSHAY STANLEY F · CIK 0001266737 · ExVP&PresConsHlthCare

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,199

Underlying: Common Stock · 20,000 shares

Expires 2013-07-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-10-014856 · doc4.xml · nonDerivative · entry 9

BARSHAY STANLEY F · CIK 0001266737 · ExVP&PresConsHlthCare

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,589

SEC source: 0001209191-10-014856 · doc4.xml · nonDerivative · entry 8

BARSHAY STANLEY F · CIK 0001266737 · ExVP&PresConsHlthCare

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,589

SEC source: 0001209191-10-014856 · doc4.xml · nonDerivative · entry 7

BARSHAY STANLEY F · CIK 0001266737 · ExVP&PresConsHlthCare

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,789

SEC source: 0001209191-10-014856 · doc4.xml · nonDerivative · entry 6

BARSHAY STANLEY F · CIK 0001266737 · ExVP&PresConsHlthCare

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,589

SEC source: 0001209191-10-014856 · doc4.xml · nonDerivative · entry 5

BARSHAY STANLEY F · CIK 0001266737 · ExVP&PresConsHlthCare

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,789

SEC source: 0001209191-10-014856 · doc4.xml · nonDerivative · entry 4

BARSHAY STANLEY F · CIK 0001266737 · ExVP&PresConsHlthCare

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,089

SEC source: 0001209191-10-014856 · doc4.xml · nonDerivative · entry 3

BARSHAY STANLEY F · CIK 0001266737 · ExVP&PresConsHlthCare

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,689

SEC source: 0001209191-10-014856 · doc4.xml · nonDerivative · entry 2

BARSHAY STANLEY F · CIK 0001266737 · ExVP&PresConsHlthCare

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,289

SEC source: 0001209191-10-014856 · doc4.xml · nonDerivative · entry 1

BARSHAY STANLEY F · CIK 0001266737 · ExVP&PresConsHlthCare

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,589

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-10-013000 · doc4.xml · derivative · entry 4

BARSHAY STANLEY F · CIK 0001266737 · ExVP&PresConsHlthCare

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 113,199

Underlying: Common Stock · 10,000 shares

Expires 2013-07-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-10-013000 · doc4.xml · nonDerivative · entry 2

BARSHAY STANLEY F · CIK 0001266737 · ExVP&PresConsHlthCare

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,589

SEC source: 0001209191-10-013000 · doc4.xml · nonDerivative · entry 1

BARSHAY STANLEY F · CIK 0001266737 · ExVP&PresConsHlthCare

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,589

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-09-022756 · doc4.xml · nonDerivative · entry 1

BARSHAY STANLEY F · CIK 0001266737 · Ex.V-P & Pres. Con. HC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,000

F1 · shares: The acquisition of the shares was subject to the achievement of performance goals approved by the Compensation Committee of the Issuer. The shares will become payable on December 31, 2011 provided that the reporting person remains continuously employed by the Issuer through that date, or, if sooner, upon the reporting person's involuntary termination of employment other than for cause.

SEC source: 0001225208-09-021845 · doc4.xml · derivative · entry 11

BARSHAY STANLEY F · CIK 0001266737 · Exec V-P Consumer Health Care

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,008

Underlying: Common Stock · 5,192 shares

Expires 2016-04-30

F3 · derivative.exercise_price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price. The option price for the grant expiring 7/01/13 will convert from $19.35 to $21.21; the option price for the grant expiring 2/22/14 will convert from $18.20 to $19.95; the option price for the grant expiring 4/24/15 will convert from $20.70 to $22.69; the option price for the grant expiring 5/18/13 will convert from $19.23 to $21.08; the option price for the grant expiring 4/30/14 will convert from $31.57 to $34.60; the option price for the grant expiring 4/30/15 will convert from $18.85 to $20.66; and the option price for the grant expiring 4/30/16 will convert from $22.91 to $25.11.

F5 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price.

F4 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions.

SEC source: 0001225208-09-021845 · doc4.xml · derivative · entry 10

BARSHAY STANLEY F · CIK 0001266737 · Exec V-P Consumer Health Care

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,738

Underlying: Common Stock · 5,262 shares

Expires 2015-04-30

F3 · derivative.exercise_price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price. The option price for the grant expiring 7/01/13 will convert from $19.35 to $21.21; the option price for the grant expiring 2/22/14 will convert from $18.20 to $19.95; the option price for the grant expiring 4/24/15 will convert from $20.70 to $22.69; the option price for the grant expiring 5/18/13 will convert from $19.23 to $21.08; the option price for the grant expiring 4/30/14 will convert from $31.57 to $34.60; the option price for the grant expiring 4/30/15 will convert from $18.85 to $20.66; and the option price for the grant expiring 4/30/16 will convert from $22.91 to $25.11.

F5 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price.

F4 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions.

SEC source: 0001225208-09-021845 · doc4.xml · derivative · entry 9

BARSHAY STANLEY F · CIK 0001266737 · Exec V-P Consumer Health Care

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,107

Underlying: Common Stock · 7,893 shares

Expires 2014-04-30

F3 · derivative.exercise_price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price. The option price for the grant expiring 7/01/13 will convert from $19.35 to $21.21; the option price for the grant expiring 2/22/14 will convert from $18.20 to $19.95; the option price for the grant expiring 4/24/15 will convert from $20.70 to $22.69; the option price for the grant expiring 5/18/13 will convert from $19.23 to $21.08; the option price for the grant expiring 4/30/14 will convert from $31.57 to $34.60; the option price for the grant expiring 4/30/15 will convert from $18.85 to $20.66; and the option price for the grant expiring 4/30/16 will convert from $22.91 to $25.11.

F5 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price.

F4 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions.

SEC source: 0001225208-09-021845 · doc4.xml · derivative · entry 8

BARSHAY STANLEY F · CIK 0001266737 · Exec V-P Consumer Health Care

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,422

Underlying: Common Stock · 6,578 shares

Expires 2013-05-18

F3 · derivative.exercise_price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price. The option price for the grant expiring 7/01/13 will convert from $19.35 to $21.21; the option price for the grant expiring 2/22/14 will convert from $18.20 to $19.95; the option price for the grant expiring 4/24/15 will convert from $20.70 to $22.69; the option price for the grant expiring 5/18/13 will convert from $19.23 to $21.08; the option price for the grant expiring 4/30/14 will convert from $31.57 to $34.60; the option price for the grant expiring 4/30/15 will convert from $18.85 to $20.66; and the option price for the grant expiring 4/30/16 will convert from $22.91 to $25.11.

F5 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price.

F4 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions.

SEC source: 0001225208-09-021845 · doc4.xml · derivative · entry 7

BARSHAY STANLEY F · CIK 0001266737 · Exec V-P Consumer Health Care

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,246

Underlying: Common Stock · 1,754 shares

Expires 2015-04-24

F3 · derivative.exercise_price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price. The option price for the grant expiring 7/01/13 will convert from $19.35 to $21.21; the option price for the grant expiring 2/22/14 will convert from $18.20 to $19.95; the option price for the grant expiring 4/24/15 will convert from $20.70 to $22.69; the option price for the grant expiring 5/18/13 will convert from $19.23 to $21.08; the option price for the grant expiring 4/30/14 will convert from $31.57 to $34.60; the option price for the grant expiring 4/30/15 will convert from $18.85 to $20.66; and the option price for the grant expiring 4/30/16 will convert from $22.91 to $25.11.

F5 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price.

F4 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions.

SEC source: 0001225208-09-021845 · doc4.xml · derivative · entry 6

BARSHAY STANLEY F · CIK 0001266737 · Exec V-P Consumer Health Care

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,246

Underlying: Common Stock · 1,754 shares

Expires 2014-02-22

F3 · derivative.exercise_price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price. The option price for the grant expiring 7/01/13 will convert from $19.35 to $21.21; the option price for the grant expiring 2/22/14 will convert from $18.20 to $19.95; the option price for the grant expiring 4/24/15 will convert from $20.70 to $22.69; the option price for the grant expiring 5/18/13 will convert from $19.23 to $21.08; the option price for the grant expiring 4/30/14 will convert from $31.57 to $34.60; the option price for the grant expiring 4/30/15 will convert from $18.85 to $20.66; and the option price for the grant expiring 4/30/16 will convert from $22.91 to $25.11.

F5 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price.

F4 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions.

SEC source: 0001225208-09-021845 · doc4.xml · derivative · entry 5

BARSHAY STANLEY F · CIK 0001266737 · Exec V-P Consumer Health Care

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 123,160

Underlying: Common Stock · 11,840 shares

Expires 2013-07-01

F3 · derivative.exercise_price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price. The option price for the grant expiring 7/01/13 will convert from $19.35 to $21.21; the option price for the grant expiring 2/22/14 will convert from $18.20 to $19.95; the option price for the grant expiring 4/24/15 will convert from $20.70 to $22.69; the option price for the grant expiring 5/18/13 will convert from $19.23 to $21.08; the option price for the grant expiring 4/30/14 will convert from $31.57 to $34.60; the option price for the grant expiring 4/30/15 will convert from $18.85 to $20.66; and the option price for the grant expiring 4/30/16 will convert from $22.91 to $25.11.

F5 · price: Pursuant to the Merger Agreement, upon the closing of the Transactions, the option was converted into an option to purchase common shares of New Merck in accordance with the exchange ratio set forth in the Merger Agreement, including an adjustment to the number of shares underlying the option and the option's exercise price.

F4 · derivative.exercise_date: The option vested and became exercisable on varying dates pursuant to the terms of the plans under which they were granted. Certain options vested in connection with the closing of the Transactions. Following the Transactions, options continue pursuant to the same terms as were applicable prior to the Transactions.

SEC source: 0001225208-09-021845 · doc4.xml · nonDerivative · entry 4

BARSHAY STANLEY F · CIK 0001266737 · Exec V-P Consumer Health Care

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 1,776

F2 · price: Pursuant to the Agreement and Plan of Merger ("Merger Agreement") by and among, inter alia, Merck & Co., Inc., formerly Schering-Plough Corporation, ("New Merck") and Merck Sharp & Dohme Corp., formerly Merck & Co., Inc., and upon the completion of the transactions contemplated therein (the "Transactions"), each common share of Schering-Plough Corporation common stock was converted into 0.5767 shares of New Merck common stock and $10.50 in cash. Any fractional share holdings were paid in cash pursuant to a formula in the Merger Agreement.

SEC source: 0001225208-09-021845 · doc4.xml · nonDerivative · entry 3

BARSHAY STANLEY F · CIK 0001266737 · Exec V-P Consumer Health Care

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 1,844

F1 · price: Pursuant to the Merger Agreement, each share of common stock of Merck Sharp & Dohme Corp. (formerly Merck & Co., Inc.) was converted to an equal number of shares of New Merck.

SEC source: 0001225208-09-021845 · doc4.xml · nonDerivative · entry 2

BARSHAY STANLEY F · CIK 0001266737 · Exec V-P Consumer Health Care

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,991

F2 · price: Pursuant to the Agreement and Plan of Merger ("Merger Agreement") by and among, inter alia, Merck & Co., Inc., formerly Schering-Plough Corporation, ("New Merck") and Merck Sharp & Dohme Corp., formerly Merck & Co., Inc., and upon the completion of the transactions contemplated therein (the "Transactions"), each common share of Schering-Plough Corporation common stock was converted into 0.5767 shares of New Merck common stock and $10.50 in cash. Any fractional share holdings were paid in cash pursuant to a formula in the Merger Agreement.

SEC source: 0001225208-09-021845 · doc4.xml · nonDerivative · entry 1

BARSHAY STANLEY F · CIK 0001266737 · Exec V-P Consumer Health Care

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,436

F1 · price: Pursuant to the Merger Agreement, each share of common stock of Merck Sharp & Dohme Corp. (formerly Merck & Co., Inc.) was converted to an equal number of shares of New Merck.

SEC source: 0001209191-10-005614 · doc4a.xml · nonDerivative · entry 2

BARSHAY STANLEY F · CIK 0001266737 · ExVP&PresConsHlthCare

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,580

F3 · shares: Pursuant to the terms of the Issuer's 2006 Stock Incentive Plan, the shares will become payable on December 31, 2011 provided that the reporting person remains continuously employed by the Issuer through that date, or, if sooner, upon the reporting person's involuntary termination of employment other than for cause.

F2 · balance_after: Reflects beneficial ownership as of November 3, 2009.

SEC source: 0001209191-10-005614 · doc4a.xml · nonDerivative · entry 1

BARSHAY STANLEY F · CIK 0001266737 · ExVP&PresConsHlthCare

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,023

F1 · shares: Distribution of net after-tax shares of common stock from performance-based share units granted on February 26, 2007. Pursuant to the terms of the Issuer's 2006 Stock Incentive Plan, the shares vested upon the completion of the transactions contemplated by the Agreement and Plan of Merger by and among, inter alia, Merck Sharp & Dohme Corp. (formerly Merck & Co., Inc.) and Merck & Co., Inc. (formerly Schering-Plough Corporation)(the "Transaction").

F2 · balance_after: Reflects beneficial ownership as of November 3, 2009.